OBJECTIVE: The aim of this study was to examine interactions between hot flushes, estrogen plus progestogen therapy (EPT), and coronary heart disease (CHD) events in postmenopausal women with CHD. METHODS: We analyzed data from the Heart and Estrogen/Progestin Replacement Study, a randomized, placebo-controlled trial of 0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate in 2,763 postmenopausal women with CHD. Hot flushes were assessed at baseline using self-administered questionnaires; women reporting bothersome hot flushes "some" to "all" of the time were considered to have clinically significant flushing. Cox regression models were used to examine the effect of EPT on risk of CHD events among women with and without significant flushing at baseline. RESULTS: The mean age of participants was 66.7 +/- 6.8 years, and 89% (n = 2,448) were white. Sixteen percent (n = 434) of participants reported clinically significant hot flushes at baseline. Among women with baseline flushing, EPT increased risk of CHD events nine-fold in the first year compared with placebo (hazard ratio = 9.01; 95% CI, 1.15-70.35); among women without baseline flushing, treatment did not significantly affect CHD event risk in the first year (hazard ratio = 1.32; 95% CI, 0.86-2.03; P = 0.07 for interaction of hot flushes with treatment). The trend toward differential effects of EPT on risk for CHD among women with and without baseline flushing did not persist after the first year of treatment. CONCLUSIONS: Among older postmenopausal women with CHD, EPT may increase risk of CHD events substantially in the first year of treatment among women with clinically significant hot flushes but not among those without hot flushes.
OBJECTIVE: The aim of this study was to examine interactions between hot flushes, estrogen plus progestogen therapy (EPT), and coronary heart disease (CHD) events in postmenopausal women with CHD. METHODS: We analyzed data from the Heart and Estrogen/Progestin Replacement Study, a randomized, placebo-controlled trial of 0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate in 2,763 postmenopausal women with CHD. Hot flushes were assessed at baseline using self-administered questionnaires; women reporting bothersome hot flushes "some" to "all" of the time were considered to have clinically significant flushing. Cox regression models were used to examine the effect of EPT on risk of CHD events among women with and without significant flushing at baseline. RESULTS: The mean age of participants was 66.7 +/- 6.8 years, and 89% (n = 2,448) were white. Sixteen percent (n = 434) of participants reported clinically significant hot flushes at baseline. Among women with baseline flushing, EPT increased risk of CHD events nine-fold in the first year compared with placebo (hazard ratio = 9.01; 95% CI, 1.15-70.35); among women without baseline flushing, treatment did not significantly affect CHD event risk in the first year (hazard ratio = 1.32; 95% CI, 0.86-2.03; P = 0.07 for interaction of hot flushes with treatment). The trend toward differential effects of EPT on risk for CHD among women with and without baseline flushing did not persist after the first year of treatment. CONCLUSIONS: Among older postmenopausal women with CHD, EPT may increase risk of CHD events substantially in the first year of treatment among women with clinically significant hot flushes but not among those without hot flushes.
Authors: Ellen B Gold; Alicia Colvin; Nancy Avis; Joyce Bromberger; Gail A Greendale; Lynda Powell; Barbara Sternfeld; Karen Matthews Journal: Am J Public Health Date: 2006-05-30 Impact factor: 9.308
Authors: Linda M Gerber; Lynnette Leidy Sievert; Katherine Warren; Thomas G Pickering; Joseph E Schwartz Journal: Menopause Date: 2007 Mar-Apr Impact factor: 2.953
Authors: Deborah Grady; David Herrington; Vera Bittner; Roger Blumenthal; Michael Davidson; Mark Hlatky; Judith Hsia; Stephen Hulley; Alan Herd; Steven Khan; L Kristin Newby; David Waters; Eric Vittinghoff; Nanette Wenger Journal: JAMA Date: 2002-07-03 Impact factor: 56.272
Authors: Alison J Huang; Deborah Grady; Vanessa L Jacoby; Terri L Blackwell; Douglas C Bauer; George F Sawaya Journal: Arch Intern Med Date: 2008-04-28
Authors: Amanda M Shearman; L Adrienne Cupples; Serkalem Demissie; Inga Peter; Christopher H Schmid; Richard H Karas; Michael E Mendelsohn; David E Housman; Daniel Levy Journal: JAMA Date: 2003-11-05 Impact factor: 56.272
Authors: Elizabeth A Jackson; Samar R El Khoudary; Sybil L Crawford; Karen Matthews; Hadine Joffe; Claudia Chae; Rebecca C Thurston Journal: J Womens Health (Larchmt) Date: 2016-07-12 Impact factor: 2.681
Authors: Rebecca C Thurston; Samar R El Khoudary; Kim Sutton-Tyrrell; Carolyn J Crandall; Ellen B Gold; Barbara Sternfeld; Hadine Joffe; Faith Selzer; Karen A Matthews Journal: Obstet Gynecol Date: 2012-04 Impact factor: 7.661
Authors: Bette J Caan; Jennifer A Emond; H Irene Su; Ruth E Patterson; Shirley W Flatt; Ellen B Gold; Vicky A Newman; Cheryl L Rock; Cynthia A Thomson; John P Pierce Journal: J Clin Oncol Date: 2012-03-19 Impact factor: 44.544
Authors: Rebecca C Thurston; Samar R El Khoudary; Kim Sutton-Tyrrell; Carolyn J Crandall; Ellen Gold; Barbara Sternfeld; Faith Selzer; Karen A Matthews Journal: Menopause Date: 2011-10 Impact factor: 2.953
Authors: Emily D Szmuilowicz; JoAnn E Manson; Jacques E Rossouw; Barbara V Howard; Karen L Margolis; Nancy C Greep; Robert G Brzyski; Marcia L Stefanick; Mary Jo O'Sullivan; Chunyuan Wu; Matthew Allison; Diederick E Grobbee; Karen C Johnson; Judith K Ockene; Beatriz L Rodriguez; Gloria E Sarto; Mara Z Vitolins; Ellen W Seely Journal: Menopause Date: 2011-06 Impact factor: 2.953
Authors: Erin Foran Wolff; Yunxiao He; Dennis M Black; Eliot A Brinton; Mathew J Budoff; Marcelle I Cedars; Howard N Hodis; Rogerio A Lobo; Joann E Manson; George R Merriam; Virginia M Miller; Fredrick Naftolin; Lubna Pal; Nanette Santoro; Heping Zhang; S Mitchell Harman; Hugh S Taylor Journal: Fertil Steril Date: 2013-01-08 Impact factor: 7.329
Authors: Rebecca C Thurston; B Delia Johnson; Chrisandra L Shufelt; Glenn D Braunstein; Sarah L Berga; Frank Z Stanczyk; Carl J Pepine; Vera Bittner; Steven E Reis; Diane V Thompson; Sheryl F Kelsey; George Sopko; C Noel Bairey Merz Journal: Menopause Date: 2017-02 Impact factor: 2.953